立优加®盐酸哌甲酯缓释片首发上市 立方制药持续发力高壁垒市场

Core Viewpoint - Lifan Pharmaceutical has launched its self-developed sustained-release methylphenidate hydrochloride tablets, marking a significant milestone in the company's growth and innovation strategy [1][2]. Group 1: Product Launch and Market Position - The sustained-release methylphenidate hydrochloride tablets, named Liyoujia, received approval from the National Medical Products Administration in April 2025 and are primarily used for treating Attention Deficit Hyperactivity Disorder (ADHD) [1]. - The product utilizes advanced three-layer osmotic pump technology for precise controlled release, ensuring rapid onset and stable efficacy throughout the day [1]. - Currently, Lifan Pharmaceutical is one of the few domestic manufacturers of anesthetic and first-class psychotropic drugs, benefiting from policy barriers and a comprehensive supply chain management system [1][2]. Group 2: Market Potential and Sales Performance - The prevalence of ADHD among adults in China is approximately 3%, while the rate for children is as high as 6.26%, indicating a significant market opportunity for methylphenidate formulations [2]. - Sales of methylphenidate sustained-release tablets in domestic sample hospitals reached approximately 350 million yuan in 2023, with an expected increase to about 430 million yuan in the first three quarters of 2024 [2]. Group 3: Strategic Partnerships and Distribution - During the launch ceremony, Lifan Pharmaceutical signed cooperation agreements with major pharmaceutical distribution companies, ensuring rapid access to medical institutions across the country [2]. - The company aims to enhance patient accessibility to medications through its partnerships with leading pharmaceutical distribution networks [2]. Group 4: Research and Development Focus - Lifan Pharmaceutical emphasizes that research and development are now viewed as core assets rather than costs, focusing on products with technical, regulatory, and financial barriers [3]. - The company plans to balance self-research and external collaborations, aiming to develop improved new drugs while also introducing first-class new drugs through partnerships [3]. - In 2024, the company's R&D investment is projected to reach approximately 93.49 million yuan, accounting for 6.16% of its revenue [2].